

# Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

Explosion of Genetic Vaccines in Animals Gets Human Attention

By [Dr. Peter McCullough](#)

Theme: [Science and Medicine](#)

Global Research, April 17, 2023

[Courageous Discourse](#) 16 April 2023

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Click the share button above to email/forward this article to your friends and colleagues. Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

\*\*\*

*The mRNA and adenoviral DNA COVID-19 vaccine debacle in humans has set populations on edge, distrustful of poorly conceived genetic technology. Meanwhile the field has advanced considerably in veterinary medicine. While these shots may protect animals from pathogens over the short term, what are the implications for our food supply? Any of the genetic material transmissible to humans through consumption? Raw or cooked? These and other questions are coming up as more information is being brought forward.*

Aida and colleagues have graphically summarized the genetic technologies in use as of 2021 in veterinary medicine. In the consumer meat category at present, only swine are of concern given the use of plasmid DNA, replication incompetent viral vector, and RNA replicon products. Do these technologies cause noninfectious diseases in the animals?


Can any of the genetic material survive denaturing during curing and cooking? How about pork intestines harvested for the production of heparin widely used in human medicine? It is conceivable that genetic incorporation of foreign RNA or DNA into humans and production of antigens for example, porcine endemic diarrhea or influenza A, could have untoward effects including autoimmunity similar to that with the COVID-19 vaccines?

# Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

Virginia Aida<sup>1,2</sup>, Vasilis C. Pliasis<sup>1,2</sup>, Peter J. Neasham<sup>1,2</sup>, J. Fletcher North<sup>1,2</sup>, Kirklin L. McWhorter<sup>1,3</sup>, Sheniqua R. Glover<sup>1,2</sup> and Constantinos S. Kyriakis<sup>1,2,4\*</sup>

<sup>1</sup> Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States,

<sup>2</sup> Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States, <sup>3</sup> Department of Chemistry, Emory University, Atlanta, GA, United States, <sup>4</sup> Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States



Aida V, Pliasis VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Front Vet Sci. 2021 Apr 15;8:654289. doi: 10.3389/fvets.2021.654289. PMID: 33937377; PMCID: PMC8083957.

**TABLE 2 |** DNA vaccines.

Species	Vaccines	Manufacturer	Pathogen	Plasmid(s)
Salmonid	Apex IHN <sup>®</sup>	Elanco (Aqua Health)	Infectious Hematopoietic Necrosis	pUK21-A2, pUK-ihnG
	Clynav	Elanco (Aqua Health)	Salmonid Alphavirus Subtype 3	PUK-SPDV-poly2#1

**TABLE 3 |** Recombinant viral vector vaccines.

Species	Vaccine	Manufacturer	Pathogen	Technology (viral-vector)
Canine	Recombitek <sup>®</sup> CDV	Boehringer Ingelheim	Canine Distemper Virus	Viral-Vector (canarypox)
Feline	PureVAX <sup>®</sup> Recombinant FeLV	Boehringer Ingelheim	Feline Leukemia Virus	Viral-Vector (canarypox)
	PureVAX <sup>®</sup> Feline Rabies	Boehringer Ingelheim	Rabies	Viral-Vector (canarypox)
Equine	ProteqFlu	Boehringer Ingelheim	Equine Influenza	Viral-Vector (canarypox)
	ALVAC <sup>®</sup> -WNV	Pfizer	West Nile Virus	Viral-Vector (canarypox)
Swine	Foster <sup>™</sup> PCV	Zoetis	Porcine Circovirus Type 2	Chimeric Viral-vector (PCV-1)
	Suvaxyn <sup>®</sup> CSF Marker	Zoetis	Classical Swine Fever virus	Chimeric Viral-vector (BVDV)
	IPED+	Merck Animal Health	Porcine Endemic Diarrhea virus	RNA Replicon (VEEV)
	Sequivity <sup>®</sup>	Merck Animal Health	Swine influenza A virus	RNA Replicon (VEEV)
Bovine	Adt.A24 FMD	GenVec	Foot and Mouth Disease	Viral-vector (adenovirus)
Avian	Trovac <sup>®</sup> -AIV H5	Boehringer Ingelheim	Avian Influenza	Viral-vector (fowlpox)
	Vectormune <sup>®</sup> AI	CEVA Biomune	Avian Influenza	Chimeric Viral-vector (HVT/MD)
	Vectormune <sup>®</sup> ND	CEVA Biomune	Newcastle Disease	Chimeric Viral-vector (HVT/MD)
	Vectormune <sup>®</sup> FP LT	CEVA Biomune	Infectious Laryngotracheitis virus	Chimeric Viral-vector (fowlpox)
	Vectormune <sup>®</sup> FP MG	CEVA Biomune	Mycoplasma Gallisepticum	Chimeric Viral-vector (fowlpox)
	Vectormune <sup>®</sup> FP-N	CEVA Biomune	Newcastle Disease	Chimeric Viral-vector (fowlpox)
	Innovax <sup>®</sup> -ND	Merck Animal Health	Newcastle Disease	Chimeric Viral-vector (HVT/MD)
	Innovax <sup>®</sup> -ND-IBD	Merck Animal Health	Newcastle disease and Infectious bursal disease	Chimeric Viral-vector (HVT/MD)
	Innovax <sup>®</sup> -ND-ILT	Merck Animal Health	Newcastle disease and infectious laryngotracheitis	Chimeric Viral-vector (HVT/MD)
	ORNAB <sup>®</sup>	Artemis Technologies, Inc.,	Rabies	Viral-vector (human adenovirus type 5)
	Raboral V-RG <sup>®</sup>	Boehringer Ingelheim	Rabies	Viral-vector (vaccinia virus)
Rabbits	Novibac <sup>®</sup> Myxo-RHD	Merck Animal Health	Rabbit Hemorrhagic Disease	Chimeric Viral-vector (myxoma virus)
	Novibac <sup>®</sup> Myxo-RHD Plus	Merck Animal Health	Rabbit Hemorrhagic Disease	Chimeric Viral-vector (myxoma virus)

Now is a good time for veterinary and human medicine including the FDA and USDA, to come together and review the published studies of these new products on genetic transmissibility to humans and its potential implications. The Aida paper does not even mention the possibility of collateral impact to humans. One can see that developers, sponsors, and authors are blinded with infatuation for molecular biology and have lost sight of biological product safety in the food supply.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

\*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Source

[Aida V, Pliasis VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Front Vet Sci. 2021 Apr 15;8:654289. doi: 10.3389/fvets.2021.654289. PMID: 33937377; PMCID: PMC8083957.](#)

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Peter McCullough](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)  
[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.  
For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)